NO774216L - Fremgangsmaate for fremstilling av benzimidazolderivater - Google Patents
Fremgangsmaate for fremstilling av benzimidazolderivaterInfo
- Publication number
- NO774216L NO774216L NO774216A NO774216A NO774216L NO 774216 L NO774216 L NO 774216L NO 774216 A NO774216 A NO 774216A NO 774216 A NO774216 A NO 774216A NO 774216 L NO774216 L NO 774216L
- Authority
- NO
- Norway
- Prior art keywords
- radical
- formula
- hydrogen
- alkyl
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title claims description 18
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title description 3
- 150000001556 benzimidazoles Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 50
- 229910052739 hydrogen Inorganic materials 0.000 claims description 38
- 239000001257 hydrogen Substances 0.000 claims description 38
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 239000007858 starting material Substances 0.000 claims description 19
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- LEVJVKGPFAQPOI-UHFFFAOYSA-N phenylmethanone Chemical compound O=[C]C1=CC=CC=C1 LEVJVKGPFAQPOI-UHFFFAOYSA-N 0.000 claims description 4
- HOHWYQSDLRTVDK-UHFFFAOYSA-N pyrimido[1,2-a]benzimidazole Chemical class N1=CC=CN2C3=CC=CC=C3N=C21 HOHWYQSDLRTVDK-UHFFFAOYSA-N 0.000 claims description 4
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 2
- ZOAMZFNAPHWBEN-UHFFFAOYSA-N 2-$l^{1}-oxidanylpropane Chemical compound CC(C)[O] ZOAMZFNAPHWBEN-UHFFFAOYSA-N 0.000 claims 1
- 241000231697 Zelus means Species 0.000 claims 1
- BQIKRTGTPBOIMK-UHFFFAOYSA-N [O]C[O] Chemical compound [O]C[O] BQIKRTGTPBOIMK-UHFFFAOYSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 239000000203 mixture Substances 0.000 description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- -1 alkyl radical Chemical class 0.000 description 39
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 34
- 239000007787 solid Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- 238000004452 microanalysis Methods 0.000 description 15
- 239000013078 crystal Substances 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- 210000001772 blood platelet Anatomy 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 238000009835 boiling Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 6
- GJYVNFASHFTWEU-UHFFFAOYSA-N 8-acetyl-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound C1CC(=O)NC2=NC3=CC(C(=O)C)=CC=C3N21 GJYVNFASHFTWEU-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 206010043554 thrombocytopenia Diseases 0.000 description 5
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012452 mother liquor Substances 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 3
- JCRWHUMNIOSWNT-UHFFFAOYSA-N 2-oxo-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazole-8-carbonitrile Chemical compound N#CC1=CC=C2N3CCC(=O)NC3=NC2=C1 JCRWHUMNIOSWNT-UHFFFAOYSA-N 0.000 description 3
- IFODSVOKJRKVAH-UHFFFAOYSA-N 5,6-di(propan-2-yloxy)-1h-benzimidazol-2-amine Chemical compound C1=C(OC(C)C)C(OC(C)C)=CC2=C1NC(N)=N2 IFODSVOKJRKVAH-UHFFFAOYSA-N 0.000 description 3
- RJIXIIOSXWJCPX-UHFFFAOYSA-N 8-benzoyl-4-methyl-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound C=1C=C2N3C(C)CC(=O)NC3=NC2=CC=1C(=O)C1=CC=CC=C1 RJIXIIOSXWJCPX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000010908 decantation Methods 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 3
- URLKBWYHVLBVBO-UHFFFAOYSA-N p-dimethylbenzene Natural products CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
- VEIXVSPCPGWULB-UHFFFAOYSA-N 1-(4-amino-3-nitrophenyl)ethanone Chemical compound CC(=O)C1=CC=C(N)C([N+]([O-])=O)=C1 VEIXVSPCPGWULB-UHFFFAOYSA-N 0.000 description 2
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical class NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 2
- JKTMZHVHKLBPEO-UHFFFAOYSA-N 3-(2-amino-5-benzoylbenzimidazol-1-yl)propanoic acid Chemical compound C=1C=C2N(CCC(O)=O)C(N)=NC2=CC=1C(=O)C1=CC=CC=C1 JKTMZHVHKLBPEO-UHFFFAOYSA-N 0.000 description 2
- WPMJALPQMIIHOE-UHFFFAOYSA-N 5-ethylsulfanyl-2-nitroaniline Chemical compound CCSC1=CC=C([N+]([O-])=O)C(N)=C1 WPMJALPQMIIHOE-UHFFFAOYSA-N 0.000 description 2
- WOIHSHXQQGYBGM-UHFFFAOYSA-N 5h-[1,3]dioxolo[4,5-f]benzimidazol-6-amine Chemical compound C1=C2NC(N)=NC2=CC2=C1OCO2 WOIHSHXQQGYBGM-UHFFFAOYSA-N 0.000 description 2
- RHIPJPVWXDTEOX-UHFFFAOYSA-N 6-methylsulfanyl-1h-benzimidazol-2-amine Chemical compound CSC1=CC=C2N=C(N)NC2=C1 RHIPJPVWXDTEOX-UHFFFAOYSA-N 0.000 description 2
- MELMCGUWWNPXAX-UHFFFAOYSA-N 7-chloro-8-methyl-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound N1=C2NC(=O)CCN2C2=C1C=C(C)C(Cl)=C2 MELMCGUWWNPXAX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical compound CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 description 1
- WYRSGXAIHNMKOL-UHFFFAOYSA-N $l^{1}-sulfanylethane Chemical compound CC[S] WYRSGXAIHNMKOL-UHFFFAOYSA-N 0.000 description 1
- OPOULJSODSJJOS-UHFFFAOYSA-N (2-amino-3h-benzimidazol-5-yl)-(4-chlorophenyl)methanone Chemical compound C1=C2NC(N)=NC2=CC=C1C(=O)C1=CC=C(Cl)C=C1 OPOULJSODSJJOS-UHFFFAOYSA-N 0.000 description 1
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 description 1
- YBDBYPQFIMSFJW-UHFFFAOYSA-N (4-chloro-3-nitrophenyl)-phenylmethanone Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC(C(=O)C=2C=CC=CC=2)=C1 YBDBYPQFIMSFJW-UHFFFAOYSA-N 0.000 description 1
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- WZXFIDXRXIOGTR-UHFFFAOYSA-N 1,3-benzodioxole-4,5-diamine Chemical compound NC1=CC=C2OCOC2=C1N WZXFIDXRXIOGTR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZCFSWYZFGJAUKK-UHFFFAOYSA-N 1,4-dimethyl-2,3-dinitrobenzene Chemical class CC1=CC=C(C)C([N+]([O-])=O)=C1[N+]([O-])=O ZCFSWYZFGJAUKK-UHFFFAOYSA-N 0.000 description 1
- ASVPUUDJBLBNEH-UHFFFAOYSA-N 1-(2-amino-3h-benzimidazol-5-yl)ethanone Chemical compound CC(=O)C1=CC=C2N=C(N)NC2=C1 ASVPUUDJBLBNEH-UHFFFAOYSA-N 0.000 description 1
- DSPHFASHOJAOKN-UHFFFAOYSA-N 1-[(7-oxobenzo[a]phenalen-2-yl)amino]anthracene-9,10-dione Chemical compound C1=CC2=CC(NC3=C4C(=O)C5=CC=CC=C5C(C4=CC=C3)=O)=CC(C=3C(=CC=CC=3)C3=O)=C2C3=C1 DSPHFASHOJAOKN-UHFFFAOYSA-N 0.000 description 1
- 125000004173 1-benzimidazolyl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N1* 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- GPMHHSJZGVOEFS-UHFFFAOYSA-N 2-Amino-5-benzoylbenzimidazole Chemical compound C1=C2NC(N)=NC2=CC=C1C(=O)C1=CC=CC=C1 GPMHHSJZGVOEFS-UHFFFAOYSA-N 0.000 description 1
- JCFDLGDOHBRADK-UHFFFAOYSA-N 2-amino-1-(4-methylphenyl)-4-phenylpyrrole-3-carbonitrile Chemical compound C1=CC(C)=CC=C1N1C(N)=C(C#N)C(C=2C=CC=CC=2)=C1 JCFDLGDOHBRADK-UHFFFAOYSA-N 0.000 description 1
- PNMKRBOIMTZVLQ-UHFFFAOYSA-N 2-amino-3h-benzimidazole-5-carbonitrile Chemical compound C1=C(C#N)C=C2NC(N)=NC2=C1 PNMKRBOIMTZVLQ-UHFFFAOYSA-N 0.000 description 1
- KIZQNNOULOCVDM-UHFFFAOYSA-N 2-hydroxyethyl(trimethyl)azanium;hydrate Chemical compound O.C[N+](C)(C)CCO KIZQNNOULOCVDM-UHFFFAOYSA-N 0.000 description 1
- VWLLPPSBBHDXHK-UHFFFAOYSA-N 3,4-diaminobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1N VWLLPPSBBHDXHK-UHFFFAOYSA-N 0.000 description 1
- RZBWGEXTRWUGBV-UHFFFAOYSA-N 3,6-dimethylbenzene-1,2-diamine Chemical compound CC1=CC=C(C)C(N)=C1N RZBWGEXTRWUGBV-UHFFFAOYSA-N 0.000 description 1
- AXJLWOZOUQAJCH-UHFFFAOYSA-N 3-(2-amino-5-cyanobenzimidazol-1-yl)propanoic acid Chemical compound N#CC1=CC=C2N(CCC(O)=O)C(N)=NC2=C1 AXJLWOZOUQAJCH-UHFFFAOYSA-N 0.000 description 1
- AFSDRVUYYAKKAE-UHFFFAOYSA-N 3-(4-benzoyl-2-nitroanilino)propanoic acid Chemical compound C1=C([N+]([O-])=O)C(NCCC(=O)O)=CC=C1C(=O)C1=CC=CC=C1 AFSDRVUYYAKKAE-UHFFFAOYSA-N 0.000 description 1
- HOYFZPFXOIOCNQ-UHFFFAOYSA-N 3-(4-cyano-2-nitroanilino)propanoic acid Chemical compound OC(=O)CCNC1=CC=C(C#N)C=C1[N+]([O-])=O HOYFZPFXOIOCNQ-UHFFFAOYSA-N 0.000 description 1
- KKPITQHNEPXHKV-UHFFFAOYSA-N 3-(5-acetyl-2-aminobenzimidazol-1-yl)propanenitrile Chemical compound CC(=O)C1=CC=C2N(CCC#N)C(N)=NC2=C1 KKPITQHNEPXHKV-UHFFFAOYSA-N 0.000 description 1
- YJHHPOVQQUWTCH-UHFFFAOYSA-N 3-(5-acetyl-2-aminobenzimidazol-1-yl)propanoic acid Chemical compound CC(=O)C1=CC=C2N(CCC(O)=O)C(N)=NC2=C1 YJHHPOVQQUWTCH-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- FSCNFDUBSHSRET-UHFFFAOYSA-N 4,5-di(propan-2-yloxy)benzene-1,2-diamine Chemical compound CC(C)OC1=CC(N)=C(N)C=C1OC(C)C FSCNFDUBSHSRET-UHFFFAOYSA-N 0.000 description 1
- UGQOAAAVARWPRF-UHFFFAOYSA-N 4,5-dimethyl-1h-benzimidazol-2-amine Chemical compound CC1=CC=C2N=C(N)NC2=C1C UGQOAAAVARWPRF-UHFFFAOYSA-N 0.000 description 1
- ZSAWWJYNDFERFN-UHFFFAOYSA-N 4,7-dimethyl-1h-benzimidazol-2-amine Chemical compound CC1=CC=C(C)C2=C1N=C(N)N2 ZSAWWJYNDFERFN-UHFFFAOYSA-N 0.000 description 1
- XBLPHYSLHRGMNW-UHFFFAOYSA-N 4-chloro-3-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC(C#N)=CC=C1Cl XBLPHYSLHRGMNW-UHFFFAOYSA-N 0.000 description 1
- HAADRTMPUSJNOI-UHFFFAOYSA-N 5,6-dichloro-1h-benzimidazol-2-amine Chemical compound ClC1=C(Cl)C=C2NC(N)=NC2=C1 HAADRTMPUSJNOI-UHFFFAOYSA-N 0.000 description 1
- POWPTEBMSHLSRA-UHFFFAOYSA-N 5,6-dimethoxy-1h-benzimidazol-2-amine Chemical compound C1=C(OC)C(OC)=CC2=C1NC(N)=N2 POWPTEBMSHLSRA-UHFFFAOYSA-N 0.000 description 1
- YPFQISHSXCFZMU-UHFFFAOYSA-N 5,6-dimethyl-1h-benzimidazol-2-amine Chemical compound C1=C(C)C(C)=CC2=C1NC(N)=N2 YPFQISHSXCFZMU-UHFFFAOYSA-N 0.000 description 1
- CMRKDXGOFRFBFT-UHFFFAOYSA-N 5-chloro-6-methyl-1h-benzimidazole Chemical compound C1=C(Cl)C(C)=CC2=C1N=CN2 CMRKDXGOFRFBFT-UHFFFAOYSA-N 0.000 description 1
- CHFVQSSDSNUKHT-UHFFFAOYSA-N 6,7-dimethyl-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound N1C(=O)CCN2C3=C(C)C(C)=CC=C3N=C21 CHFVQSSDSNUKHT-UHFFFAOYSA-N 0.000 description 1
- AKDHQKIGPDFQSP-UHFFFAOYSA-N 6,8-dimethyl-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound C1CC(=O)NC2=NC3=CC(C)=CC(C)=C3N21 AKDHQKIGPDFQSP-UHFFFAOYSA-N 0.000 description 1
- FCEFZMUBBPBDBN-UHFFFAOYSA-N 6-ethylsulfanyl-1h-benzimidazol-2-amine Chemical compound CCSC1=CC=C2N=C(N)NC2=C1 FCEFZMUBBPBDBN-UHFFFAOYSA-N 0.000 description 1
- CBXXFKUEWZXGAE-UHFFFAOYSA-N 7,8-dimethoxy-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound N1=C2NC(=O)CCN2C2=C1C=C(OC)C(OC)=C2 CBXXFKUEWZXGAE-UHFFFAOYSA-N 0.000 description 1
- ZVNVORZDOSCQFY-UHFFFAOYSA-N 7-(1-hydroxyethyl)-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound N1C(=O)CCN2C3=CC(C(O)C)=CC=C3N=C21 ZVNVORZDOSCQFY-UHFFFAOYSA-N 0.000 description 1
- IMQLCZMXGMSLQG-UHFFFAOYSA-N 7-acetyl-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound N1C(=O)CCN2C3=CC(C(=O)C)=CC=C3N=C21 IMQLCZMXGMSLQG-UHFFFAOYSA-N 0.000 description 1
- MHNNGFWZFMRICE-UHFFFAOYSA-N 8-(1-hydroxyethyl)-10h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound O=C1C=CN2C3=CC=C(C(O)C)C=C3NC2=N1 MHNNGFWZFMRICE-UHFFFAOYSA-N 0.000 description 1
- NOMZRPUINHBDAZ-UHFFFAOYSA-N 8-(1-hydroxyethyl)-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound C1CC(=O)NC2=NC3=CC(C(O)C)=CC=C3N21 NOMZRPUINHBDAZ-UHFFFAOYSA-N 0.000 description 1
- PNCXFUNZJXQLCB-UHFFFAOYSA-N 8-butanoyl-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound C1CC(=O)NC2=NC3=CC(C(=O)CCC)=CC=C3N21 PNCXFUNZJXQLCB-UHFFFAOYSA-N 0.000 description 1
- DQOQDGKAPKGFGY-UHFFFAOYSA-N 8-ethylsulfanyl-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound C1CC(=O)NC2=NC3=CC(SCC)=CC=C3N21 DQOQDGKAPKGFGY-UHFFFAOYSA-N 0.000 description 1
- QVPKZUZPHCWEHJ-UHFFFAOYSA-N 8-ethylsulfinyl-4,10-dihydro-3h-pyrimido[1,2-a]benzimidazol-2-one Chemical compound C1CC(=O)NC2=NC3=CC(S(=O)CC)=CC=C3N21 QVPKZUZPHCWEHJ-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- ZFDIRQKJPRINOQ-HWKANZROSA-N Ethyl crotonate Chemical compound CCOC(=O)\C=C\C ZFDIRQKJPRINOQ-HWKANZROSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006480 benzoylation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- QPJDMGCKMHUXFD-UHFFFAOYSA-N cyanogen chloride Chemical compound ClC#N QPJDMGCKMHUXFD-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- NDRUTHFTDCUQOA-UHFFFAOYSA-N methyl 2-[4-(2-aminoacetyl)phenoxy]acetate Chemical compound COC(=O)COC1=CC=C(C(=O)CN)C=C1 NDRUTHFTDCUQOA-UHFFFAOYSA-N 0.000 description 1
- LNDNYPUTPRJGSQ-UHFFFAOYSA-N methyl 3-(2-amino-5-benzoylbenzimidazol-1-yl)propanoate Chemical compound C=1C=C2N(CCC(=O)OC)C(N)=NC2=CC=1C(=O)C1=CC=CC=C1 LNDNYPUTPRJGSQ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- YWANGSCDWBUSBK-UHFFFAOYSA-N n-(5-chloro-2-nitrophenyl)acetamide Chemical compound CC(=O)NC1=CC(Cl)=CC=C1[N+]([O-])=O YWANGSCDWBUSBK-UHFFFAOYSA-N 0.000 description 1
- ALBBQFWHUCTZFM-UHFFFAOYSA-N n-methyl-1h-benzimidazol-2-amine Chemical compound C1=CC=C2NC(NC)=NC2=C1 ALBBQFWHUCTZFM-UHFFFAOYSA-N 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- UXCDUFKZSUBXGM-UHFFFAOYSA-N phosphoric tribromide Chemical compound BrP(Br)(Br)=O UXCDUFKZSUBXGM-UHFFFAOYSA-N 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ZFDIRQKJPRINOQ-UHFFFAOYSA-N transbutenic acid ethyl ester Natural products CCOC(=O)C=CC ZFDIRQKJPRINOQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB51426/76A GB1585965A (en) | 1976-12-09 | 1976-12-09 | 3,4-dihydropyrimido (1,2 - )benzimidazol - 2(1h) - ones |
| GB3334177 | 1977-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO774216L true NO774216L (no) | 1978-06-12 |
Family
ID=26261828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO774216A NO774216L (no) | 1976-12-09 | 1977-12-08 | Fremgangsmaate for fremstilling av benzimidazolderivater |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4167569A (hu) |
| JP (1) | JPS5390296A (hu) |
| AT (1) | AT359068B (hu) |
| AU (1) | AU514427B2 (hu) |
| CA (1) | CA1086727A (hu) |
| CH (1) | CH633291A5 (hu) |
| CS (1) | CS199696B2 (hu) |
| DD (1) | DD133330A5 (hu) |
| DE (1) | DE2754930A1 (hu) |
| ES (1) | ES464862A1 (hu) |
| FI (1) | FI63577C (hu) |
| FR (1) | FR2373543A1 (hu) |
| GR (1) | GR65298B (hu) |
| HU (1) | HU176540B (hu) |
| IE (1) | IE45924B1 (hu) |
| IL (1) | IL53507A (hu) |
| IT (1) | IT1143729B (hu) |
| NL (1) | NL7713658A (hu) |
| NO (1) | NO774216L (hu) |
| NZ (1) | NZ185823A (hu) |
| PL (1) | PL107142B1 (hu) |
| SE (1) | SE435385B (hu) |
| SU (1) | SU843751A3 (hu) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE51802B1 (en) * | 1979-12-03 | 1987-04-01 | Fujisawa Pharmaceutical Co | Quinazoline derivatives,processes for their preparation and pharmaceutical compositions containing them |
| CA1157858A (en) | 1979-12-03 | 1983-11-29 | Ikuo Ueda | Quinazoline derivatives |
| DE3208218A1 (de) * | 1982-03-06 | 1983-09-08 | Basf Ag, 6700 Ludwigshafen | Isoindolinfarbstoffe und deren verwendung |
| RU2453312C1 (ru) * | 2010-11-10 | 2012-06-20 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" | Средство, проявляющее антиагрегантную и антитромбогенную активности |
| JP6272846B2 (ja) | 2012-06-27 | 2018-01-31 | ４エスツェー ディスカバリー ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌、自己免疫性炎症及びｃｎｓ疾患の処置のためのビフルオロジオキサラン−アミノ−ベンゾイミダゾールキナーゼ阻害剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3468888A (en) * | 1967-04-11 | 1969-09-23 | Smithkline Corp | 2-substituted pyrimido(1,2-a) benzimidazoles |
| US3988340A (en) * | 1975-01-23 | 1976-10-26 | Bristol-Myers Company | 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones |
| US4072679A (en) * | 1976-06-15 | 1978-02-07 | E. R. Squibb & Sons, Inc. | 1,4- AND 4,10-DIHYDRO-4-OXO-PYRIMIDO (1,2-A)-benzimidazole-3-carboxylic acids, esters and amides |
-
1977
- 1977-11-23 US US05/855,003 patent/US4167569A/en not_active Expired - Lifetime
- 1977-11-28 IE IE2408/77A patent/IE45924B1/en unknown
- 1977-11-29 CA CA291,976A patent/CA1086727A/en not_active Expired
- 1977-11-30 NZ NZ185823A patent/NZ185823A/xx unknown
- 1977-12-01 IL IL53507A patent/IL53507A/xx unknown
- 1977-12-01 AU AU31121/77A patent/AU514427B2/en not_active Expired
- 1977-12-05 HU HU77IE816A patent/HU176540B/hu unknown
- 1977-12-07 DD DD7700202450A patent/DD133330A5/xx unknown
- 1977-12-07 ES ES464862A patent/ES464862A1/es not_active Expired
- 1977-12-07 GR GR54931A patent/GR65298B/el unknown
- 1977-12-08 NO NO774216A patent/NO774216L/no unknown
- 1977-12-08 FR FR7737011A patent/FR2373543A1/fr active Granted
- 1977-12-08 PL PL1977202753A patent/PL107142B1/pl unknown
- 1977-12-08 SE SE7713958A patent/SE435385B/sv unknown
- 1977-12-08 CH CH1507777A patent/CH633291A5/de not_active IP Right Cessation
- 1977-12-09 AT AT883677A patent/AT359068B/de not_active IP Right Cessation
- 1977-12-09 DE DE19772754930 patent/DE2754930A1/de not_active Withdrawn
- 1977-12-09 IT IT30558/77A patent/IT1143729B/it active
- 1977-12-09 JP JP14866977A patent/JPS5390296A/ja active Pending
- 1977-12-09 CS CS778270A patent/CS199696B2/cs unknown
- 1977-12-09 NL NL7713658A patent/NL7713658A/xx not_active Application Discontinuation
- 1977-12-09 SU SU772552626A patent/SU843751A3/ru active
- 1977-12-09 FI FI773724A patent/FI63577C/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI63577B (fi) | 1983-03-31 |
| CA1086727A (en) | 1980-09-30 |
| US4167569A (en) | 1979-09-11 |
| PL202753A1 (pl) | 1978-10-09 |
| DE2754930A1 (de) | 1978-06-15 |
| AT359068B (de) | 1980-10-27 |
| ATA883677A (de) | 1980-03-15 |
| FR2373543B1 (hu) | 1980-05-16 |
| SE7713958L (sv) | 1978-06-10 |
| IE45924L (en) | 1978-06-09 |
| AU3112177A (en) | 1979-06-07 |
| FI773724A (fi) | 1978-06-10 |
| IL53507A (en) | 1981-07-31 |
| JPS5390296A (en) | 1978-08-08 |
| FR2373543A1 (fr) | 1978-07-07 |
| CS199696B2 (en) | 1980-07-31 |
| NZ185823A (en) | 1980-08-26 |
| IE45924B1 (en) | 1982-12-29 |
| AU514427B2 (en) | 1981-02-12 |
| NL7713658A (nl) | 1978-06-13 |
| GR65298B (en) | 1980-08-01 |
| HU176540B (en) | 1981-03-28 |
| DD133330A5 (de) | 1978-12-27 |
| IL53507A0 (en) | 1978-03-10 |
| FI63577C (fi) | 1983-07-11 |
| PL107142B1 (pl) | 1980-01-31 |
| CH633291A5 (de) | 1982-11-30 |
| ES464862A1 (es) | 1979-01-01 |
| IT1143729B (it) | 1986-10-22 |
| SU843751A3 (ru) | 1981-06-30 |
| SE435385B (sv) | 1984-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK174161B1 (da) | Anellerede indolderivater, fremgangsmåde til deres fremstilling og fremgangsmåde til fremstilling af farmaceutisk præparat indeholdende dem | |
| DE60013803T2 (de) | Tetracyclische azepinoindol verbindungen als 5-ht rezeptor liganden | |
| AU778735B2 (en) | Fused azepinone cyclin dependent kinase inhibitors | |
| FI86425C (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva 6-benzoxazinyl- och 6-benzotiazinyl-2,3,4,5- tetrahydropyridazin-3-oner. | |
| KR20160103986A (ko) | N-벤질 트립탄트린 유도체, 및 이의 제조 방법 및 적용 | |
| JP2003507480A (ja) | 異性体の縮合ピロロカルバゾール類およびイソインドロン類 | |
| DK164704B (da) | 3,6-disubstituerede triazolo-oe3,4-aaa-ftalazinderivater, fremgangsmaade til fremstilling deraf, udgangsforbindelse til anvendelse i fremgangsmaaden samt anvendelse af og farmaceutisk praeparat indeholdende forbindelserne | |
| CN109134463B (zh) | β-咔啉类5型磷酸二酯酶抑制剂及其制备方法和用途 | |
| NO151287B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 9-hydrazono-6,7,8,9-tetrahydro-4h-pyrido(1,2-a)-pyrimidinderivater | |
| HUT75121A (en) | Bis-imide derivatives of tri-and tetraamines and pharmaceutical compositions containing them | |
| Guo et al. | Molecular hybrid design, synthesis, in vitro and in vivo anticancer evaluation, and mechanism of action of N-acylhydrazone linked, heterobivalent β-carbolines | |
| JPH04273878A (ja) | 複素環式化合物及びその製法 | |
| NO774216L (no) | Fremgangsmaate for fremstilling av benzimidazolderivater | |
| NZ207981A (en) | Pyrimidones and pharmaceutical compositions | |
| US4495187A (en) | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents | |
| HU224435B1 (hu) | Benzodiazepin-származékok, eljárás előállításukra, alkalmazásukra és ezeket tartalmazó gyógyászati készítmények | |
| CS203184B2 (en) | Process for preparing new pyrroloquinoxalinones and pyrrolobenzodiazepinones | |
| JPH0733743A (ja) | ２−アリール−４−キノリノール誘導体 | |
| RU2057754C1 (ru) | Гетероциклические соединения или их кислотно-аддитивные соли | |
| US4372956A (en) | 5, 10-Dihydroimidazo[2,1-b]quinazolines and pharmaceutical compositions containing them | |
| US3312699A (en) | Asymmetric triazino indoles | |
| NZ229899A (en) | Benzazepine and isoindole derivatives and pharmaceutical compositions | |
| DD215545A5 (de) | Verfahren zur herstellung eines (1,2,4)triazolo (4,3-a)chin-oxalin-4-amin-derivats | |
| GB1585965A (en) | 3,4-dihydropyrimido (1,2 - )benzimidazol - 2(1h) - ones | |
| US3235552A (en) | 2, 7-di-(tertiary aminoalkylene)-2, 7-dihydroanthra-[1:9-5:10]-dipyrazoles |